Clinical trials: Stage IB Melanoma
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Melanoma (Skin)
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
RATIONALE: Gathering information about vitamin D supplementation and sun exposure in patients with melanoma may help doctors learn more about the disease and find what may affect cancer relapse.
- Trial name
- NCT00672321
- Testing
- gene expression analysis, mutation analysis, polymorphism analysis
- Where
- United Kingdom
- Volunteers
- 2,774 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Recurrent Melanoma, Stage IA Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
- Conditions
- Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma
- Trial name
- NCT00003895
- Testing
- HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm Metastases, Melanoma
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
Background: Cancers in other parts of the body often spread to the liver, developing tumors which in many instances cannot be removed with surgery.
- Conditions
- Neoplasm Metastases, Melanoma, Colorectal Neoplasms
- Trial name
- NCT01336985
- Testing
- Irinotecan, Chemoembolization, Drug-Eluting Beads
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8
The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
This phase I trial investigates the impact of cefazolin before surgery on the microbiome in patients with stage I-II melanoma. Antibiotics, such as cefazolin, given at the time of surgery may cause a significant change in the…
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Trial name
- NCT04875728
- Testing
- Cefazolin, Resection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene…
- Trial name
- NCT05983237
- Testing
- Fluzoparib Camrelizumab Temozolomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jun Guo
Melanoma
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma
This study is an open-label, Phase Ib clinical study to evaluate recombinant human GM-CSF herpes simplex virus intratumoral injection (OrienX010) in combination with recombinant humanized anti-PD-1 monoclonal antibody infusion…
- Trial name
- NCT04197882
- Testing
- OrienX010 Combination with Toripalimab injection
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma, Solid Tumors
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
This Phase Ib/II study is a clinical study to explore the efficacy and safety of BL-M08D1 for injection in patients with locally advanced or metastatic melanoma and other solid tumors.
- Trial name
- NCT07841925
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, Melanoma
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
- Trial name
- NCT02974725
- Testing
- LXH254, LTT462, Trametinib
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin.
- Trial name
- NCT01029873
- Testing
- Cisplatin, ALT-801
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Altor BioScience
Advanced Melanoma, Non-small Cell Lung Cancer
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab.
- Conditions
- Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03502330
- Testing
- APX005M, Cabiralizumab, Nivolumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Yale University
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Locally Advanced or Metastatic NRAS Mutant Melanoma
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
In the phase Ib, the primary purpose is to establish the maximum tolerated dose (MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally administered combination.
- Trial name
- NCT01781572
- Testing
- LEE011, MEK162
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 102 people
- Sponsor
- Pfizer
Melanoma
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
This study is an open, single-center, multi-cohort phase Ib exploratory study, and 50 subjects are planned to be enrolled to observe the objective response rate of each subject.
- Trial name
- NCT05451407
- Testing
- TQB2618 injection, Toripalimab injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Melanoma (Skin)
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897481
- Testing
- gene expression analysis, mutation analysis, diagnostic laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Stage IV Melanoma
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Primary: Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.
- Trial name
- NCT01133977
- Testing
- Lenvatinib, Dacarbazine
- Where
- 27 sites in United States, Germany and 3 more
- Volunteers
- 97 people
- Sponsor
- Eisai Inc.
Malignant Melanoma
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-wild type (WT), metastatic, or unresectable locally advanced melanoma who…
- Trial name
- NCT03178851
- Testing
- Atezolizumab, Cobimetinib
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Advanced Ovarian Cancer, Malignant Melanoma
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
This is a phase 1b study for patients with metastatic (cancer has spread to various parts of the body) melanoma and ovarian cancer.
- Trial name
- ACTIVATE (NCT03158935)
- Testing
- Cyclophosphamide, Fludarabine, Pembrolizumab
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Melanoma
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma.
- Trial name
- NCT00272415
- Testing
- INO-1001, temozolomide
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.